Market revenue in 2023 | USD 271.5 million |
Market revenue in 2030 | USD 594.0 million |
Growth rate | 11.8% (CAGR from 2023 to 2030) |
Largest segment | Functional genomics |
Fastest growing segment | Pathway Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery |
Key market players worldwide | Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genomics market will help companies and investors design strategic landscapes.
Functional genomics was the largest segment with a revenue share of 31.38% in 2023. Horizon Databook has segmented the Sweden genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2018 to 2030.
In Sweden, increased usage of genomics in clinical practice for proper diagnosis and treatment is driving the market. Moreover, Genomic Medicine Sweden (GMS) was started in 2017. This initiative aims to contribute to personalized medicine and enhance healthcare in the country. The main focus of the GMS initiative will be individuals with cancer, rare disorders, and infectious disorders.
In addition, the collaboration between SciLifeLab Clinical Genomics platform and GMS to develop precision diagnostics has enabled the use of WGS for rare diseases in hospitals. Similarly, in April 2022, Danish National Genome Center and Genomic Medicine Sweden entered into a partnership to develop advanced precision medicine.
This initiative aims to develop and implement novel solutions and models to deliver genomic-based precision medicine at the national level. Thus, increasing adoption of genome sequencing applications in hospitals and laboratories has further boosted market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden genomics market , including forecasts for subscribers. This country databook contains high-level insights into Sweden genomics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account